Cargando…
Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter
BACKGROUND: Malignant ascites is a pathological condition caused by intra- or extra-abdominal disseminated cancer. The object of treatment is palliation. In search of an effective and minimally invasive palliative treatment of malignant ascites placement of a permanent intra peritoneal catheter has...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548747/ https://www.ncbi.nlm.nih.gov/pubmed/26346641 http://dx.doi.org/10.1177/2058460115579934 |
_version_ | 1782387227283685376 |
---|---|
author | Meier, Michelle Mortensen, Frank V. Madsen, Hans Henrik Torp |
author_facet | Meier, Michelle Mortensen, Frank V. Madsen, Hans Henrik Torp |
author_sort | Meier, Michelle |
collection | PubMed |
description | BACKGROUND: Malignant ascites is a pathological condition caused by intra- or extra-abdominal disseminated cancer. The object of treatment is palliation. In search of an effective and minimally invasive palliative treatment of malignant ascites placement of a permanent intra peritoneal catheter has been suggested. PURPOSE: To evaluate our experiences with treatment of malignant ascites by implantation of a permanent PleurX catheter. MATERIAL AND METHODS: A retrospective study was conducted, comprising 20 consecutive patients with terminal cancer, who had a permanent PleurX catheter implanted because of malignant ascites in the period from February to November 2014. Using the patients’ medical records, we retrieved data on patients and procedures. RESULTS: The technical success rate was 100%. Catheter patency was 95.2%, one catheter was removed due to dislocation. Ten patients (50.0%) experienced minor adverse events. No procedural difficulties were reported and there was no need for additional treatment of malignant ascites after catheter implantation. Median residual survival after catheter implantation was 27 days. CONCLUSION: Implantation of a permanent PleurX catheter is a minimally invasive and effective procedure with only minor adverse events and a high rate of catheter patency in patients with malignant ascites caused by terminal cancer disease. |
format | Online Article Text |
id | pubmed-4548747 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-45487472015-09-04 Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter Meier, Michelle Mortensen, Frank V. Madsen, Hans Henrik Torp Acta Radiol Open Research BACKGROUND: Malignant ascites is a pathological condition caused by intra- or extra-abdominal disseminated cancer. The object of treatment is palliation. In search of an effective and minimally invasive palliative treatment of malignant ascites placement of a permanent intra peritoneal catheter has been suggested. PURPOSE: To evaluate our experiences with treatment of malignant ascites by implantation of a permanent PleurX catheter. MATERIAL AND METHODS: A retrospective study was conducted, comprising 20 consecutive patients with terminal cancer, who had a permanent PleurX catheter implanted because of malignant ascites in the period from February to November 2014. Using the patients’ medical records, we retrieved data on patients and procedures. RESULTS: The technical success rate was 100%. Catheter patency was 95.2%, one catheter was removed due to dislocation. Ten patients (50.0%) experienced minor adverse events. No procedural difficulties were reported and there was no need for additional treatment of malignant ascites after catheter implantation. Median residual survival after catheter implantation was 27 days. CONCLUSION: Implantation of a permanent PleurX catheter is a minimally invasive and effective procedure with only minor adverse events and a high rate of catheter patency in patients with malignant ascites caused by terminal cancer disease. SAGE Publications 2015-07-03 /pmc/articles/PMC4548747/ /pubmed/26346641 http://dx.doi.org/10.1177/2058460115579934 Text en © The Foundation Acta Radiologica 2015 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(http://www.uk.sagepub.com/aboutus/openaccess.htm). |
spellingShingle | Research Meier, Michelle Mortensen, Frank V. Madsen, Hans Henrik Torp Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter |
title | Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter |
title_full | Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter |
title_fullStr | Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter |
title_full_unstemmed | Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter |
title_short | Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter |
title_sort | malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548747/ https://www.ncbi.nlm.nih.gov/pubmed/26346641 http://dx.doi.org/10.1177/2058460115579934 |
work_keys_str_mv | AT meiermichelle malignantascitesinpatientswithterminalcanceriseffectivelytreatedwithpermanentperitonealcatheter AT mortensenfrankv malignantascitesinpatientswithterminalcanceriseffectivelytreatedwithpermanentperitonealcatheter AT madsenhanshenriktorp malignantascitesinpatientswithterminalcanceriseffectivelytreatedwithpermanentperitonealcatheter |